Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

| More on:
woman testing substance in laboratory dish, csl share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have lifted more than 2% into the green this past month of trade, outpacing the broader market in that time.

The biotech giant held its annual general meeting (AGM) on Tuesday, and its chair and CEO made several key remarks.

The announcement wasn't labelled as price-sensitive, but there are notable takeouts intelligent investors are paying attention to.

Both leaders made it clear that the company's outlook remains robust despite some shareholder concerns around remuneration and recent strategic shifts.

Here's what investors should know from the AGM that could impact CSL shares in FY25.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL1 Oct 20231 Oct 2024Zoom ▾Nov '23Jan '24Mar '24May '24Jul '24Sep '24Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24www.fool.com.au

CSL shares in focus following AGM

CSL's CEO, Dr Paul McKenzie, gave a lengthy address that covered an equally lengthy list of subjects for the biotech's shareholders.

McKenzie reaffirmed the company's financial guidance for FY25, with revenue growth expected to land between 5% to 7%.

Net profit is also projected to grow by 10% to 13%, reaching US$3.2 – $3.3 billion.

Dr McKenzie also said CSL is well-positioned to "deliver annualised double-digit earnings growth over the medium term".

I'd say this is an important point as many of the long-term price targets for CSL shares are based on this pace of growth being sustained.

Aside from the financials, the CEO continued investment in research and development, focusing on expanding product offerings within its core therapeutic areas.

Meanwhile, chair Brian McNamee also addressed the meeting and made a particular note on CSL Vifor.

CSL Vifor, which saw recent acquisitions to boost its nephrology and iron markets, aims to maintain growth in European markets while addressing pricing challenges.

It has now been over two years since we closed the acquisition of Vifor Pharma. We saw then, as we do now, a company with the capabilities, competencies and adjacencies to CSL, that would contribute to our long-term growth agenda.

This view has not changed, but shareholders will be aware that the business has experienced several near-term challenges. We were prepared for some of these, but others were unexpected.

This is disappointing, but I am confident that the leadership group have the right plans in place to deliver growth from CSL Vifor over the long-term.

The acquisition may or may not be a major growth lever for the company moving forward. But CSL's chair certainly believes it will be.

Longer-term, the focus remains the same as it always has for the biotech giant. Bringing medicines to those in need. Per McNamee:

Our investment has laid the foundation, and with the right skills and talent, our people will maximise the value from them. This will put us in an excellent position to continue to deliver our medicines to our patients whilst maintaining sustainable profitable growth into the future.

This will come from the therapeutic areas we focus on. There remains significant unmet need across these: patients who are not being helped and communities that need protection against infectious disease.

Shareholder concerns on remuneration

If the performance of CSL shares in early FY25 is anything to go by, shareholders mightn't be that encouraged. The stock is down more than 2% since then.

McNamee addressed anticipated shareholder dissent over executive remuneration, balancing the talk of creating value and the need for competitive global pay structures.

As a multinational corporation, it operates across several jurisdictions, but its executives are primarily located in the United States.

We compete for talent in that context: it is essential to our performance and our long-term growth. Our remuneration structure needs to attract and retain talented people across the globe: including those who can navigate the complex science and manufacturing that underpins CSL.

While CSL's board believes in the current remuneration structure's alignment with shareholder interests, McNamee acknowledged the discontent:

Your Board strongly believes our overall remuneration framework is aligned with this goal, and fit for the purpose of attracting top tier, global leaders who will steer the next phase of growth for our shareholders.

But we hear your discontent this year with some aspects of our approach and, of course, I'm disappointed in that. I want you to know that we are listening, and we will carefully consider the feedback we receive.

Foolish takeaway

There's several talking points that could impact CSL shares following the biotech's AGM. Management remains constructive on the future, including divisions like CSL Vifor.

In the last 12 months, the stock is up 27%.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »